Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Amazon, AstraZeneca, CME, Cisco and General Electric

Read MoreHide Full Article

For Immediate Release

Chicago, IL – May 13, 2020 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include (AMZN - Free Report) , AstraZeneca (AZN - Free Report) , CME Group (CME - Free Report) , Cisco Systems (CSCO - Free Report) and General Electric (GE - Free Report) .

Here are highlights from Tuesday’s Analyst Blog:

Top Stock Reports for Amazon, AstraZeneca and CME Group

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including, AstraZeneca and CME Group. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Amazon was a standout performer in the pre-Covid market and it has done even better during the pandemic, with the stock up +32.1% over the past year vs. +3.9% for the S&P 500. While we can reasonably expect these trends to continue going forward, the Zacks analyst points to some issues of concern like delivery delays and accelerating coronavirus-related expenses that might weigh on near-term profitability.

Strengthening AWS services contributed well to top-line growth in the March quarter. Moreover, AWS gained solid traction among healthcare workers, medical researchers, educational institutions and government organizations during the reported quarter owing to coronavirus management initiatives.

Further, Prime momentum owing to fast grocery services and strong content portfolio continued to benefit Amazon. Further, improving Alexa skills and expanding smart home product offerings were tailwinds.

(You can read the full research report on Amazon here >>>)

Shares of AstraZeneca have gained +13.6% over the past six months against the Zacks Large Cap Pharmaceuticals industry’s rise of +6%. The Zacks analyst believes that AstraZeneca’s newer drugs, mainly cancer medicines Lynparza, Tagrisso and Imfinzi, should keep driving revenues in 2020. Its pipeline is strong with abundance of catalysts lined up for 2020.

AstraZeneca beat Q1 estimates for both earnings and sales. Its products like Nexium, Crestor and Seroquel are facing generic competition, which is hurting sales. The diabetes franchise also faces stiff competition while pricing pressure is hurting sales in the respiratory unit. Also, the coronavirus outbreak may hurt its profits in 2020.

However, AstraZeneca has engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like China. Cost-cutting efforts should drive earnings.

(You can read the full research report on AstraZeneca here >>>)

CME Group’s shares have lost -12.9% over the past three months against the Zacks Securities and Exchanges industry’s fall of -1.7%. The Zacks analyst believes that CME Group remains well-poised for growth on strong market position driven by varied derivative product lines.

Efforts to expand and cross sell through strategic alliances, acquisitions, new product initiatives and a stable global presence bode well. Product innovation and growing proportion of volume from customers outside the United States have been aiding results. However, escalating expenses are likely to put pressure on margin expansion.

Its diversified product portfolio is significantly exposed to volatile interest rate, firm government regulations and limited credit availability in unstable capital and credit market. CME Group’s first-quarter earnings per share of $2.33 beat the Zacks Consensus Estimate by 4.5% and improved 43.8% year over year.  

(You can read the full research report on CME Group here >>>)

Other noteworthy reports we are featuring today include Cisco Systems and General Electric.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>

Join us on Facbook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339               

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit information about the performance numbers displayed in this press release.